# Commons Capital

> Commons Capital is a VC fund backing Health Care and Biotechnology. See 8 investments, check sizes, portfolio and contact details. Updated Sep 2026.

- Type: VC Fund
- Location: Brookline, United States
- Total investments: 8
- Last investment: May 2011
- Lead investor: 13%
- Last updated: Sep 2026
- LinkedIn: https://www.linkedin.com/company/commons-capital/
- Website: http://www.commonscapital.com

Commons Capital is an early-stage venture capital fund focused on clean energy, environment, education, and healthcare sectors.

## Contacts

5 contacts available for Commons Capital. Shizune tracks 1 team members at Commons Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/commons-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 38% |
| Biotechnology | 2 | 25% |
| Manufacturing | 2 | 25% |
| Energy | 1 | 13% |
| Women's | 1 | 13% |

12 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 4 | 50% |
| Series A | 2 | 25% |
| Funding Round | 2 | 25% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| William Osborn | Investment Manager | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| HistoRx | HistoRx is developing theranostic solutions to towards individualized patient care. HistoRx's proprietary technology delivers objective and reproducible multiparametric analysis of proteins in tissue, providing insights into cancer treatment. | $2.6M |  | May 27, 2011 |  |
| Combinent Biomedical Systems | Combinent Biomedical Systems, Inc., a women's healthcare company, offers multi-segmented vaginal rings that allow the delivery of hydrophobic and hydrophilic molecules, proteins, and other large molecules. It focuses on transvaginal delivery of drugs targeting women's reproductive endocrinology disorders, as well as diabetes, obesity, andinfectious diseases. Combinent Biomedical Systems, Inc. was incorporated in 2000 and is based in Lexington, Massachusetts. | $500K |  | Dec 17, 2009 |  |
| Claros Diagnostics | Claros Diagnostics, Inc. is creating products to move in-vitro medical diagnostic tests out of the laboratory and into the hands of physicians and patients. | $4M | Series B | Mar 23, 2009 |  |
| HistoRx | HistoRx is developing theranostic solutions to towards individualized patient care. HistoRx's proprietary technology delivers objective and reproducible multiparametric analysis of proteins in tissue, providing insights into cancer treatment. | $6M | Series B | Oct 24, 2007 |  |
| Claros Diagnostics | Claros Diagnostics, Inc. is creating products to move in-vitro medical diagnostic tests out of the laboratory and into the hands of physicians and patients. | $7.8M | Series A | Jan 19, 2007 |  |
| Protonex Technology Corporation | Protonex is opening up a world of new energy by revolutionizing the way you can use portable power. Tap into tomorrow's power today and find the product that best suits your changing portable power needs. Protonex power solutions offer numerous advantages over batteries and generators | $9M | Series B | Apr 04, 2005 |  |
| Medical Metrx Solutions | Medical Metrx Solutions, Inc. (formerly Medical Media Systems) is a medical technology and services company providing diagnostic quality 3-D virtual models of patient anatomy built from CT and MR scan data using the company’s proprietary modeling software. The company’s models — which contain more precise quantitative measurement informationthan competitors’ offerings — are provided to interventional radiologists and vascular surgeons who use them for pre-operative planning and post-operative surveillance of their patients’ conditions. The company was acquired by AIG Altaris Health Partners in 2005. | $3.5M | Series B | Dec 17, 2003 |  |
| H2Gen Innovations | H2Gen Innovations, Inc., of Alexandria , Virginia develops, manufactures and markets on-site hydrogen appliances that provide a significant breakthrough for the existing industrial hydrogen market and will be a key enabling technology for the emerging hydrogen economy. The H2Gen hydrogen generator module (HGM) converts natural gas to hydrogenusing a unique steam methane reformer, producing 2,000 scf/hr. of up to “five nines” pure hydrogen. The all-in cost of hydrogen produced with the HGM at the point of delivery is 35% to 65% less than existing conventional methods of producing and delivering hydrogen to target end-use customers. They believe that they have the superior technology for on-site hydrogen production in regard to output, purity and price for a remarkably small appliance. The company was formed in February 2001 by a team of engineers who saw the market opportunity, and who had been working on the concept and technology for the preceding seven years. | $4.7M | Series A | Oct 09, 2001 |  |

8 of 8 investments shown.

## Co-investors
- Accelerated Technologies Partners — VC Fund, 2 deals together
- [Bioventures Investors](https://shizune.co/investors/profile/bioventures-investors) — VC Fund, 2 deals together
- [Brook Venture Partners](https://shizune.co/investors/profile/brook-venture-partners) — VC Fund, 2 deals together
- [Maven Capital Partners](https://shizune.co/investors/profile/maven-capital-partners) — VC Fund, 2 deals together
- Navigator Technology Ventures — VC Fund, 2 deals together
- [Oxford Bioscience Partners](https://shizune.co/investors/profile/oxford-bioscience-partners) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Commons Capital invest in?

Commons Capital invests primarily in Health Care, Biotechnology and Manufacturing startups, most often at Series B and Series A stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Commons Capital?

Public channels for Commons Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Commons Capital?

The team at Commons Capital includes William Osborn (Investment Manager). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co